Clinical Trials
12 trialsNCT03645928 2026-05-15
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Phase 2 Terminated
NCT04083599 2026-05-06
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT02817633 2025-10-28
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
Phase 1 Active not recruiting
NCT05180799 2025-06-15
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
BioAtla, Inc.
Phase 1/2 Active not recruiting
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06839105 2025-05-31
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Recruiting
NCT04993677 2025-05-11
A Study of SEA-CD40 Given With Other Drugs in Cancers
Seagen Inc.
Phase 2 Completed
NCT04452214 2023-07-14
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
Phase 1 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed